NCT03859752View on ClinicalTrials.gov

TR1801-ADC in Patients With Tumors That Express c-Met

PHASE1SuspendedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 14, 2019

Primary Completion Date

July 4, 2023

Study Completion Date

December 31, 2023

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

TR1801-ADC

Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin

Trial Locations (4)

21287

John Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore

80045

University of Colorado, Aurora

90033

University of Southern California Norris Comprehensive Cancer Center, Los Angeles

98109

University of Washington / Seattle Cancer Care, Seattle

Sponsors
All Listed Sponsors
lead

Open Innovation Partners, Inc.

INDUSTRY